Drug Discovery & Research
Clinical Trial AI Delivers 82-Fold Return in Tufts Economic Model, But Humans Still Hold the Reins
New analysis quantifies up to $21 million in value from Medable's monitoring agent for phase 3 oncology trials, establishing the first major ROI benchmark as the industry moves from pilot programs to production deployment.
Health AI Central Editorial Team·August 27, 2026
Drug Discovery & Research
AI Monitoring Agent Delivers 82x ROI and $21 Million Gains in Cancer Drug Trials, Tufts Analysis Finds
First evidence-based financial modeling of agentic AI in drug development shows Medable's clinical monitoring system accelerates oncology programs by 10 weeks while slashing on-site monitoring costs.
Health AI Central Editorial Team·August 14, 2026